CW November 2004
Volume 13Issue Number 11 November 2004 ISSN 10593802 Updated Recommendation for Breast Cancer Adjuvant TherapyAdjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer should include an aromatase inhibitor in order to lower the risk of tumor recurrence, according to an updated Technology Assessment from the American Society of Clinical Oncology (ASCO).
Go to Previous Page Go to Next Page Source & Additional Reading E. P. Winer et al., Updated Technology Assessment from the American Society of Clinical Oncology (ASCO). Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW November 2004Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
